Treatment for newly diagnosed light chain amyloidosis
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new drug that targets two proteins on the cells causing amyloidosis, aiming to reduce the harmful protein buildup in the body. It is for people who have just been diagnosed with this condition and have not yet had other treatments for it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been newly diagnosed with AL amyloidosis.
- Your blood tests must show a certain level of abnormal light chain proteins.
- You should be generally active and able to care for yourself.
- Your organs (like kidneys, liver, blood counts) need to work well enough, with some limits.
- You cannot have had previous treatments for your plasma cell disease.
- Women who can have children and men must agree to use birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new cell therapy using your own immune cells (genetically modified to target amyloid-producing cells) to treat light chain amyloidosis that hasn't responded to standard treatments. The goal is to help patients whose disease has come back or stopped responding to previous therapies.
This trial tests a new drug called teclistamab for people newly diagnosed with advanced (stage IIIB) AL amyloidosis, a condition where abnormal proteins build up and damage organs. The goal is to see if teclistamab can help control the disease.
This trial tests a type of immunotherapy called CAR-T cells for people newly diagnosed with severe AL amyloidosis, a disease where abnormal proteins damage organs, especially the heart. It aims to see if this treatment can help control the disease.
This early-stage trial tests a new drug called anselamimab for AL amyloidoma—a rare condition where abnormal protein deposits form tumors in one part of your body. The study aims to see if this drug can help shrink or control these deposits in patients who have a visible, removable tumor.
This trial tests a combination of two targeted drugs for people newly diagnosed with AL amyloidosis. You may qualify if you have a specific genetic marker (t(11;14)) and your organs are working well enough.
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.